Additionally, AGM‐330, another novel peptide binding to NCL, is being explored along with Paclitaxel (AGM‐330‐PTXL) for its antagonistic properties in lung cancer, though research into its efficacy and application continues.96 The gene discussed is NUCLEOLIN; the disease is lung carcinoma.